ArticleBMC cancer2022
The effect of recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- Incidence, Risk Factors, and Management of Radiotherapy-Related Skin Toxicity in Rectoanal Cancer Patients: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Global hotspots and research trends of radiation-induced skin injury: a bibliometric analysis from 2004 to 2023.Frontiers in oncology · 2024Pooled it
- Advances in the Prevention and Treatment of Radiation Skin Injury: Mechanisms, Pharmacological Interventions, and Applications of Novel Dressings.International journal of nanomedicine · 2026Review
- Mechanism-Inspired Biomaterials and Regenerative Therapies for Radiation-Induced Skin Injury.International journal of nanomedicine · 2026Review
- [Clinical expert consensus on application of topical growth factors in chronic wounds (2025 edition)].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2025Article
- Reconsidering the Role of V-Y Fasciocutaneous Flaps in Abdominoperineal Resection Reconstruction With the Addition of a Pelvic Exclusion Mesh.Plastic and reconstructive surgery. Global open · 2025Article
- Sanhuang Fukang oil alleviates X-ray-induced skin injury by reducing inflammation and apoptosis: anFrontiers in pharmacology · 2025Article
- Cutaneous Metastasis of Rectal Cancer as a Diagnostic Challenge: A Clinical Case and Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- The effect of various interventions on the prevention of radiation dermatitis: a network meta-analysis.American journal of translational research · 2024Review
- Chinese clinical practice guidelines for the prevention and treatment of radiation-induced dermatitis.Precision radiation oncology · 2023Article
- Management of Radiation-induced Tissue Injuries: A Review of Current Treatment Strategies.Plastic and reconstructive surgery. Global open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOur previous study reported that recombinant human epidermal growth factor (rhEGF)-triggered EGFR internalization promoted radioresistance. Here, we aimed to evaluate the effect of rhEGF on the skin protection of rectal and anal cancer patients receiving radiotherapy.
methodsOne hundred and ninety-three rectal and anal cancer patients who received radiotherapy were prospectively enrolled from January 2019 to December 2020. To perform self-controlled study, the left and right pelvic skin area (separated by midline) were randomly assigned to the rhEGF and control side. The association between radiation dermatitis and factors including rhEGF, the dose of radiotherapy and tumor distance from anal edge were analyzed.
resultsAmong 193 enrolled patients, 41 patients (21.2%) did not develop radiation dermatitis, and 152 patients (78.8%) suffered radiation dermatitis on at least one side of pelvic skin at the end of radiotherapy. For the effect on radiation dermatitis grade, rhEGF had improved effect on 6 (4.0%) patients, detrimental effect on 2 (1.3%) patients, and no effect on 144 (94.7%) patients. Whereas for the effect on radiation dermatitis area, rhEGF showed improved effect on the radiation dermatitis area of 46 (30.2%) patients, detrimental effect on 15 (9.9%) patients, and no effect on 91 (59.9%) patients. The radiation dermatitis area of rhEGF side was significantly smaller than that of control side (P = 0.0007).
conclusionsrhEGF is a skin protective reagent for rectal and anal cancer patients receiving radiotherapy.
trial registrationChinese Clinical Trial Registry identifier: ChiCTR1900020842; Date of registration: 20/01/2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.